Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation & Amortization (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Accumulated Depreciation & Amortization over the past 12 years, most recently at $500000.0 for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $500000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $500000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $500000.0, changed 0.0%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $500000.0 at Viridian Therapeutics, Inc.\DE, roughly flat from $500000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for VRDN hit a ceiling of $522000.0 in Q4 2023 and a floor of $25000.0 in Q2 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $210000.0 (2021), compared with a mean of $253750.0.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 84.13% in 2021 and later surged 150.0% in 2022.
  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation & Amortization stood at $120000.0 in 2021, then surged by 150.0% to $300000.0 in 2022, then skyrocketed by 74.0% to $522000.0 in 2023, then decreased by 4.21% to $500000.0 in 2024, then changed by 0.0% to $500000.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $500000.0 (Q4 2025), $500000.0 (Q4 2024), and $522000.0 (Q4 2023) per Business Quant data.